| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ouabain Octahydrate | 11018-89-6 | sc-201548 sc-201548A | 1 g 5 g | $194.00 $734.00 | 11 | |
Ouabain is another cardiac glycoside that inhibits Na+/K+-ATPase activity and affects ion transport. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
12β-Hydroxydigitoxin is a well-known cardiac glycoside that inhibits Na+/K+-ATPase activity, leading to increased intracellular sodium levels and altered ion transport. | ||||||
Aldosterone | 52-39-1 | sc-210774 sc-210774A sc-210774B sc-210774C sc-210774D sc-210774E | 2 mg 5 mg 10 mg 50 mg 100 mg 250 mg | $259.00 $213.00 $317.00 $1550.00 $3074.00 $7637.00 | 1 | |
Aldosterone regulates Na+/K+-ATPase expression and activity, potentially influencing FXYD6. | ||||||
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $102.00 | 6 | |
Cortisol can influence electrolyte balance and Na+/K+-ATPase activity, possibly impacting FXYD6 function. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin can modulate Na+/K+-ATPase activity, which might indirectly affect FXYD6's role. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can influence Na+/K+-ATPase activity, potentially affecting FXYD6 function. | ||||||
Angiotensin II, Human | 4474-91-3 | sc-363643 sc-363643A sc-363643B sc-363643C | 1 mg 5 mg 25 mg 100 mg | $51.00 $100.00 $310.00 $690.00 | 3 | |
Angiotensin II, through its regulatory effects on electrolyte balance, can influence Na+/K+-ATPase and potentially FXYD6. | ||||||
ADP | 58-64-0 | sc-507362 | 5 g | $54.00 | ||
ATP is the primary energy source for Na+/K+-ATPase, and its availability can indirectly influence FXYD6 function. | ||||||